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Most would recognize the situation: a young 
person presents with autistic features. While 
the patient himself has clear cut symptoms 
of autism classifiable according to any 
known classificatory system that is cur-
rently in use, his older brother has similar, 
yet different set of social deficits in that he 
has no friends and is being bullied due to his 
odd ways of communication and behaviors. 
Teacher reports clearly relay symptoms of 
Attention Deficit Hyperactivity Disorder 
(ADHD) in your patient and parents report 
that the young person fidgets and twitches. 
While exploring the “tic” history, your regis-
trar reminds you that he has only had motor 
tics but you notice him sniffing repeatedly. 
When asked about the sniffing, the parents 
confirm that he has had it for quite some 
time but attributes it to allergy as it comes 
and goes, although with no other associated 
features of allergy. You also find out that 
a paternal uncle is “socially awkward,” dad 
had tics during childhood and that there is 
history of obsessive compulsive behaviors 
(OCB) in paternal aunt and grandmother. 
As a doctor you are concerned about the 
nature, degree, and functional impact of the 
varying symptoms on your patient’s daily 
life in order to develop an appropriate man-
agement plan. However you are also aware of 
the need to communicate the nature of your 
patient’s symptoms to other professionals 
who are involved in his care, to his school 
for attracting additional support, and to the 
parents who are trying to make sense of the 
different sets of difficulties their two boys 
are presenting with, and seeking answers as 
to why this has happened and what can be 
done. In the meantime your registrar is get-
ting exhausted trying to match the criteria 
as per the current version of the Diagnostic 
and Statistical Manual (DSM) for Autism, 
Tourette Syndrome, ADHD, and so on, and 
asks whether he would qualify for a diagno-
sis of Tourette Syndrome now that he has 
been noted to have “sniffing,” a vocal tic, 
which together with the multiple motor tics 
would get the tick of approval for such a 
diagnosis.
Nosology, cliNical criteria, aNd 
discrimiNaNt validity
Debate on the definition, nosology, and 
clinical features has been re-ignited in the 
case of autism with the proposed revision of 
the criteria in DSM V (Skuse, 2012; Swedo 
et al., 2012). While the “nosology counts” 
for the prevalence rate (Fisch, 2012), clini-
cal criteria is important for diagnosing and 
subtyping disorders (Witwer and Lecavalier, 
2008), and diagnosis is critical for manage-
ment and service provision (Nassar et al., 
2009), are we loosing the essence of neu-
rodevelopmental disorders by arguing 
about who should be counted in or out? In 
this regard, would we be justified in suggest-
ing that the older sibling in the above case 
scenario is not having a clinical problem, 
and therefore not include him as a “case” in 
your genetic analysis of this family? What 
are the implications of the tics in this case; 
is it an unrelated co-morbidity, or part of 
the phenotypic presentation of underlying 
neurodevelopmental gene(s) abnormali-
ties shared by other members of the family 
such as the paternal uncle, dad, paternal 
aunt, and grandmother? Is the ADHD in 
your patient linked to Autism, Tourette 
Syndrome, or both, or neither, and is the 
OCB in the female members of the family 
an alternate phenotypic expression of the 
putative Tourette gene(s), and what is the 
relationship of that, if any, to your patient’s 
autistic symptoms?
Complexities in genotype–phenotype 
relationship and differences of opinion 
as to where you draw the line for a devia-
tion or deficit to be counted as a disease 
 condition are not new or uncommon in 
medicine. The diagnostic criteria for hyper-
tension based on blood pressure level, is a 
case in point. Another example is that of 
diabetes, a clinically and genetically het-
erogeneous condition. While most profes-
sionals and lay public are now familiar with 
the two subtypes namely Type 1 and Type 
2 diabetes, would it be important to rec-
ognize yet another condition called matu-
rity onset diabetes of the young (MODY)? 
The answer is yes, as identifying MODY 
can guide management and more specifi-
cally, further subtyping of MODY based on 
genotypes can lead to individualized treat-
ment such as the use of sulfonylureas in 
HNF1A and HNF4A mutations (Gardner 
and Tai, 2012). It will also have implica-
tions for identification and prognostication 
in family members. Clearly the solution to 
such heterogeneity is not changing the 
definition of diabetes to include or exclude 
the different subtypes, but a prudent and 
common sense approach to the “use” of the 
diagnosis. While communicating to the lay 
public, diabetes might be the best starting 
point, while communicating to profes-
sional colleagues, Type 1 or 2 or MODY 
would be appropriate and while selecting 
patients for pharmacotherapy research into 
the effectiveness of sulfonylureas, further 
subtyping to MODY1, 2, 3, etc. based on 
genotype would be warranted.
geNetic heterogeNeity leads to 
cliNical heterogeNeity
Does the case of MODY suggest a paral-
lel to the realization that “autism” may be 
“autisms” and “Tourettes” may involve a 
spectrum of tics and related behaviors? 
However, the situation is more complex 
and challenging when it comes to neu-
rodevelopmental disorders as they have 
poor discriminant validity with  differing 
clinical phenotypes sharing the same 
 neuro- cognitive profile or genetic under-
pinnings. By the same token, the same 
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disorder would depend on the definition 
of what is defined as a case. For example, 
personality traits such as being meticulous 
and neat and tidy are common in the gen-
eral population as opposed to obsessive 
compulsive disorder that is clinically sig-
nificant. There may be an inherent tension 
between determining how common it is for 
epidemiological purposes and for identify-
ing cases early in the community vs. clini-
cal diagnosis that would guide treatment. 
Such differences in case definition based on 
its utility are not uncommon, just as every 
case of breast cancer is not the same for 
the purpose of clinical diagnosis, treatment 
options, course, and prognosis. Also the 
definition of a “case” is quite different for 
early identification in the community such 
as the presence of a breast lump, vs. indica-
tion for specific chemotherapy or surgical 
options based on pathology report and 
staging. Yet for genetic research into breast 
cancer, neither of the above considerations 
would be sufficient. The same would be rel-
evant in the case of autism, where for early 
identification in the community, a “breast 
lump” approach would be needed with 
anyone showing early signs and symptoms 
getting the benefit of further assessment 
and appropriate intervention, while for 
providing educational support, the cogni-
tive, and functional level would need to be 
taken into consideration. However there is 
a significant dilemma when funding and 
support are determined by the diagnostic 
label rather than the adaptive functioning 
or other considerations.
There is no doubt that changing the 
criteria on blood pressure level would 
change the prevalence rate of hyperten-
sion in the community. However identify-
ing those with borderline levels of blood 
pressure reading would be important for 
the purpose of prevention and early inter-
vention. Thus it would seem that instead 
of changing the definition and criteria to 
achieve the various goals and functions, 
we need to strive for further refinement in 
categorizing and subtyping autism within 
the dimensional framework. It would be 
a great help if nosology of developmental 
disorders can facilitate the diagnostician 
through subtyping based on family his-
tory, neuro-cognitive characteristics, or 
symptom dimensions which would then 
allow early identification using behavioral 
telltale signs and genetic testing, choice of 
difference in the expression of the underly-
ing genotype with female members of the 
family presenting with OCB and male mem-
bers with tics (Eapen et al., 1993). It has also 
been shown that there are sex-specific dif-
ferences in the topographic segregation and 
functionality of brain regions and that the 
presence of circulating testosterone is essen-
tial for the development of the substantia 
nigra region in the neonatal period and to 
a lesser extent in the final maturation in the 
peripubertal period (Veliskova and Moshe, 
2001). Similarly, the sex-specific imprint-
ing of NRXN4/CNTNAP2, CTNNA3, and 
LRRTM1 is known to have dramatic and 
variable effects on levels of gene expres-
sion and the parent-of-origin phenotypic 
inheritance patterns (Oudejans et al., 2004; 
Francks et al., 2007).
Phenotypic variability can also be 
affected by non-genetic factors, or “second 
hits” such as prematurity, perinatal trauma, 
injury, hypoxia, oxidative stress, infections, 
inflammations and autoimmunity, neural 
and psychosocial stressors, or other envi-
ronmental modulators through epigeentics 
(Herbert, 2010). For example, an early envi-
ronmental insult could alter the epigenetic 
programming with consequent changes in 
neural function (Zhang and Meaney, 2010). 
Exploring these neurobiological underpin-
nings can lead to a better understanding of 
the pathogenetic mechanisms. Again taking 
the example of MODY, there may be a lesson 
here for genotype–phenotype interactions 
and appropriate individualized care.
diagNostic utility: help or 
hiNdraNce?
Would not it be futile to expect the varying 
gene abnormalities and the manifestations 
of overlapping genetically determined syn-
aptic processes that influence development 
to yield categorical clinical conditions? This 
debate is at the heart of the controversy 
about defining autism – one that favors 
a broad concept of neuro-diversity where 
autistic features are considered as a natural 
human variation and the other a narrow 
one. But for diagnostic purposes, there is a 
need to define a cut off to indicate normal 
vs. abnormal. By and large in psychiatry a 
clinical diagnosis of a disorder implies that 
there is significant deviation, distress, and/
or dysfunction (the three D’s) caused by the 
clinical symptoms in question. However, 
the prevalence of these traits or clinical 
genetic abnormality can lead to no clini-
cal symptoms, or subtle subclinical fea-
tures that can only be identified through 
in-depth clinical or cognitive testing, or 
full blown clinical syndrome. Evidence is 
mounting on the overlap in genetic abnor-
malities found in different neurodevelop-
mental disorders (Eapen, 2011a) but how 
can disorders with differing clinical pheno-
types share the same genetic underpinning 
and vice versa?
Available research data in Autism, 
Tourette Syndrome, and ADHD suggests 
the role of specific, yet overlapping neuronal 
circuitry. These interconnected neural sys-
tems can be linked to functionally relevant 
anatomic areas and pathways that influence 
specific cognitive or behavioral domain, 
the programming of which are genetically 
modulated during development and medi-
ated through a range of molecular pathways 
and interacting neurotransmitter systems 
(Eapen, 2011b). Elucidating the molecular 
mechanisms involved in these disorders can 
provide an invaluable window for under-
standing the neural wiring that regulates 
higher brain functions. In the competitive 
and dynamic molecular environment asso-
ciated with synaptogenesis it is not surpris-
ing to find that the timing and dose effects 
associated with disruptions, duplications, 
and dysregulation of the relevant genes/
ligands can render varying pathogenic 
consequences for brain, mind, and behav-
ior (Bottos et al., 2011). An imbalance in 
the excitatory/inhibitory ratio in local 
and extended neuronal circuits caused by 
genetic alterations is one example. Such 
events maybe sufficient but not essential, 
or essential but not sufficient, in producing 
certain behavioral profile or clinical condi-
tion, thus accounting for the variability in 
clinical presentations. Phenotypic variabil-
ity could also be due to the genes converging 
on a common neurodevelopmental pathway 
resulting in abnormal development across 
disorders and broad domains and yet carry-
ing distinct neuro-cognitive and behavioral 
profiles. The penetrance of the different co-
morbidities may also be related to the dose 
effects of gene abnormality or the timing 
of events when different neuronal regions 
and circuitry are being formed, as may be 
the influence of gender. The “extreme male 
brain” hypothesis in autism (Baron-Cohen, 
2002) is noteworthy here as is the suggestion 
that in TS, there may be a gender dependent 
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brain plasticity. Hence, as the genetically 
programmed but environmentally modu-
lated developmental process progresses, 
diagnosis will need to be seen as a means 
to assist rather than a hindrance.
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therapeutic options,  clinical prognostica-
tion, etc., However research into autism 
phenotypes is in its infancy and currently 
there is no robust replicated evidence on 
reliable subtypes which made the DSM V 
to amalgamate the various subtypes that 
existed in DSM IV into a single category 
of ASD. Perhaps there is no evidence 
because we got the subgrouping wrong 
in DSM IV? It is hoped that progress in 
identifying homogenous sub types using 
the broad autism phenotype and linking it 
with genotypes and endophenotypes would 
offer such possibilities in the future. In the 
meantime DSM V has suggested the use of 
“specifiers,” such as severity and whether 
the child has intellectual disability or a lan-
guage delay in the diagnostic evaluation.
Development is a dynamic process and 
genetically mediated deficits and conse-
quent functional impairments involve 
activity-dependent synapse development 
that depends on postnatal learning, envi-
ronment, and experiences. Thus the devel-
opmental trajectory may change as it is 
influenced by other factors in the early 
formative years of a child’s life, and so 
will the diagnosis. This would mean that 
one child may lose a diagnostic label while 
another may pick up clinical symptoms and 
co-morbidities. On a positive note, this gives 
the opportunity for prevention and early 
intervention that would have the potential 
to alter the course of development toward 
a neurotypical profile and/or prevent the 
progression of the clinical condition by 
exploiting the neuronal maturation and 
